Clinical Care Options Breast Cancer This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Immunotherapy: A Review of Key Clinical Studies
Learning Module - David R. Gandara, MD; Daniel M. Geynisman, MD; Sara Hurvitz, MD, FACP; Elias Jabbour, MD; Shaji Kumar, MD; Brian Rini, MD, FACP; Tiffany A. Traina, MD; and Heather A. Wakelee, MD, each provide an analysis of key presentations on cancer immunotherapy from the 2016 clinical oncology meeting in Chicago. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - September 23, 2016 Category: Cancer & Oncology Source Type: research

How I Am Using CDK4/6 Inhibitors for My Patients With Hormone Receptor –Positive MBC
Discussion - Are you considering CDK4/6 inhibitors as part of your treatment armamentarium for patients with hormone receptor –positive metastatic breast cancer? Dr. Jahanzeb provides insights from his experience. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - September 21, 2016 Category: Cancer & Oncology Source Type: research

Immunotherapy: A Review of Key Clinical Studies
Slideset - David R. Gandara, MD; Daniel M. Geynisman, MD; Sara Hurvitz, MD, FACP; Elias Jabbour, MD; Shaji Kumar, MD; Brian Rini, MD, FACP; Tiffany A. Traina, MD; and Heather A. Wakelee, MD, provide an analysis of key presentations on cancer immunotherapy from the 2016 Clinical Oncology meeting in Chicago. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - September 19, 2016 Category: Cancer & Oncology Source Type: research

Empowering Nurses to Improve the Care of Patients With Metastatic Breast Cancer
Slideset - In this downloadable slideset from the CCO Breast Cancer nurse meeting series, Kathy A. Pratt, BSN, RN, OCN, CBCN, and Lillie D. Shockney, RN, BS, MAS, provide expert perspective on optimizing management of patients with advanced or metastatic breast cancer. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - September 19, 2016 Category: Cancer & Oncology Source Type: research

Breast Cancer: A Review of Key Clinical Studies
Learning Module - Sara Hurvitz, MD, FACP, and Tiffany A. Traina, MD, provide their expert analysis of key breast cancer presentations from the 2016 ASCO Annual Meeting in Chicago. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - August 24, 2016 Category: Cancer & Oncology Source Type: research

Breast Cancer: A Review of Key Clinical Studies
Slideset - In this downloadable slideset, Sara Hurvitz, MD, FACP, and Tiffany A. Traina, MD, review important presentations in breast cancer from the 2016 ASCO meeting in Chicago. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - August 16, 2016 Category: Cancer & Oncology Source Type: research

PALOMA-2: Addition of Palbociclib to Frontline Letrozole Significantly Improves PFS in Postmenopausal ER+/HER2- Advanced Breast Cancer
Slideset - Palbociclib + letrozole achieved longest improvement in PFS seen to date for frontline treatment of ER+/HER2- advanced breast cancer. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - June 14, 2016 Category: Cancer & Oncology Source Type: research

PHEREXA: No PFS Benefit of Adding Pertuzumab to Trastuzumab + Capecitabine in HER2+ MBC Progressing on or After Trastuzumab-Based Therapy
Slideset - Addition of pertuzumab to trastuzumab and capecitabine improved median OS by 8 months in patients with HER2-positive metastatic breast cancer who previously progressed during/after trastuzumab-based therapy but did not meet the primary endpoint of the study. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - June 9, 2016 Category: Cancer & Oncology Source Type: research

MA.17R: Reduced Risk of Recurrence With Extending Adjuvant Letrozole Beyond 5 Yrs in Postmenopausal Women With Early-Stage Breast Cancer
This study conducted by the Canadian Cancer Trials Group is the first to show that extending aromatase inhibitor therapy beyond 5 years reduces the risk of disease recurrence. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - June 7, 2016 Category: Cancer & Oncology Source Type: research

ABC Trials Joint Analysis: TC vs TaxAC in High-Risk, HER2-Negative Early Breast Cancer
Slideset - Treatment with TaxAC superior to TC in pooled analysis of women with resected high-risk HER2-negative early breast cancer. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - June 7, 2016 Category: Cancer & Oncology Source Type: research

Atezolizumab + Nab-Paclitaxel Well Tolerated and Active in Metastatic TNBC
Slideset - Phase Ib trial with combination therapy with atezolizumab and nab-paclitaxel showed safety profile similar to each agent alone and produced durable responses in patients with mTNBC. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - June 7, 2016 Category: Cancer & Oncology Source Type: research

Phase II MONARCH 1: CDK4/6 Inhibitor Abemaciclib in HR+/HER2- MBC After Chemotherapy
Slideset - Abemaciclib monotherapy was active in patients with heavily pretreated HR+/HER2- MBC and showed no new safety signals. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - June 6, 2016 Category: Cancer & Oncology Source Type: research

KRISTINE: Neoadjuvant T-DM1 + Pertuzumab vs Chemotherapy With Trastuzumab + Pertuzumab in HER2+ EBC
Slideset - Phase III investigation of neoadjuvant T-DM1 plus pertuzumab showed a favorable safety profile but lower clinical response rate compared with chemotherapy with trastuzumab plus pertuzumab in HER2-positive early breast cancer. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - June 6, 2016 Category: Cancer & Oncology Source Type: research

Phase III MF07-01 Trial: Impact of Initial Local Resection on Stage IV Breast Cancer Survival
Slideset - With 5-year follow-up, local surgery followed by systemic therapy associated with significant improvement in OS vs initial systemic therapy with local therapy for localized progression in patients with MBC at presentation. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - June 6, 2016 Category: Cancer & Oncology Source Type: research